Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Modeling the next-generation of rhabdomyosarcoma organoids to predict effective drug combinations [methylation]

ABSTRACT: Rhabdomyosarcoma (RMS) is the main form of pediatric soft-tissue sarcoma. Its cure rate has not improved in the last 20 years notably following relapse, and the lack of reliable preclinical models has so far hampered the design of new therapies. This is particularly true for highly heterogeneous fusion-negative RMS (FNRMS). Although methods have been proposed to establish FNRMS organoids, their efficiency remains limited to date, both in terms of derivation rate and ability to accurately mimic the original tumor. Here, we present the development of a next-generation 3D-organoid model derived from relapsed adult and pediatric FNRMS. This model preserves the molecular features of the patients’ tumors and is expandable for several months in 3D, reinforcing its interest to drug combination screening with longitudinal efficacy monitoring. As a proof-of-concept, we demonstrated its preclinical relevance by reevaluating the therapeutic opportunities of targeting apoptosis in FNRMS from a streamlined approach based on transcriptomic data exploitation.

ORGANISM(S): Homo sapiens

PROVIDER: GSE248182 | GEO | 2023/12/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Modeling the next-generation of rhabdomyosarcoma organoids to predict effective drug combinations [scRNAseq]

Project description:Rhabdomyosarcoma (RMS) is the main form of pediatric soft-tissue sarcoma. Its cure rate has not improved in the last 20 years notably following relapse, and the lack of reliable preclinical models has so far hampered the design of new therapies. This is particularly true for highly heterogeneous fusion-negative RMS (FNRMS). Although methods have been proposed to establish FNRMS organoids, their efficiency remains limited to date, both in terms of derivation rate and ability to accurately mimic the original tumor. Here, we present the development of a next-generation 3D-organoid model derived from relapsed adult and pediatric FNRMS. This model preserves the molecular features of the patients’ tumors and is expandable for several months in 3D, reinforcing its interest to drug combination screening with longitudinal efficacy monitoring. As a proof-of-concept, we demonstrated its preclinical relevance by reevaluating the therapeutic opportunities of targeting apoptosis in FNRMS from a streamlined approach based on transcriptomic data exploitation.

2023-12-19 | GSE248178 | GEO

Modeling the next-generation of rhabdomyosarcoma organoids to predict effective drug combinations [RNAseq]

2023-12-19 | GSE248177 | GEO

Modeling the next-generation of rhabdomyosarcoma organoids to predict effective drug combinations [Exome panel]

2023-12-19 | GSE248176 | GEO

The 3D chromatin landscape of rhabdomyosarcoma [ChIP-Seq]

Project description:Rhabdomyosarcoma (RMS) is a pediatric soft tissue cancer with no precision therapy available for affected patients. We hypothesized that with a general paucity of known mutations in RMS, chromatin structural driving mechanisms are essential for tumor proliferation. Thus, we carried out high-depth in situ Hi-C in representative cell lines and patient-derived xenografts to understand chromatin architecture in each major RMS subtype. We report a comprehensive 3D chromatin structural analysis and characterization of fusion-positive (FP-RMS) and fusion-negative rhabdomyosarcoma (FN-RMS). We have generated spike-in in situ Hi-C chromatin interaction maps for the commonest FP-RMS and FN-RMS cell lines, and compared our data with patient derived xenograft (PDX) models. In our studies we uncover common and distinct structural elements in large Mb-scale chromatin compartments, tumor-essential genes within variable topologically associating domains, and unique patterns of structural variation. This study enables a comprehensive resource for contextualizing gene regulation events in RMS, and high-depth chromatin interactivity maps for identification of functionally critical chromatin domains in this tumor.

2023-06-13 | GSE215202 | GEO

The 3D chromatin landscape of rhabdomyosarcoma [HiC]

2023-06-13 | GSE215172 | GEO

Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance

Project description:Rhabdomyosarcoma (RMS) is an aggressive pediatric cancer. Despite robust expression of myogenic regulatory factors, RMS cells are blocked in a proliferative state and do not terminally differentiate. The extent to which the skeletal muscle lineage is represented in RMS tumors and the mechanisms leading to developmental arrest, remain elusive. Here, we used single-cell RNA sequencing (scRNAseq) to resolve RMS subpopulations under basal conditions as well as under genetic perturbation of the fusion protein PAX3:FOXO1 (P3F1).

2022-12-02 | GSE218974 | GEO

PROX1 transcription factor is a master transcriptional regulator and essential for the stemness and growth of rhabdomyosarcoma

Project description:Rhabdomyosarcoma (RMS) is an aggressive pediatric cancer in need of novel therapies. Here we show that the PROX1 transcription factor, which is essential for myoblast differentiation, is highly expressed in RMS tumors. We demonstrate that PROX1 regulates RMS cell proliferation, stemness and rhabdosphere formation in vitro and RMS tumor formation in mouse xenograft models. By using proximity labeling and mass spectrometry, we found that PROX1 interacts with the NuRD and CoREST (HDAC) complexes. PROX1 depletion reprogrammed the RMS transcriptome to resemble benign mesenchymal stem cells and repressed previously identified RMS effector transcripts, placing it upstream of these genes. Our studies reveal a major role of PROX1-HDAC interaction in RMS and give insights for novel therapeutic targets.

2022-08-31 | GSE145171 | GEO

Homo sapiens

Project description:Affymetrix SNP array data for pediatric rhabdomyosarcoma (RMS)

| PRJNA176458 | ENA

A MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting [RNA-seq]

Project description:Rhabdomyosarcoma (RMS) is a pediatric mesenchymal-derived malignancy encompassing Fusion Positive (FP)-RMS expressing PAX3/7-FOXO1 and Fusion Negative (FN)-RMS often mutated in the RAS pathway. RMS expresses the master myogenic transcription factor MYOD that, paradoxically, is unable to support differentiation while essential for tumor cell survival. We identify here SKP2, an oncogenic E3-ubiquitin ligase, as a critical driver of tumorigenesis in FN-RMS. SKP2 is overexpressed in RMS at the highest levels among several adult and pediatric cancers and its expression is maintained by MYOD through an intronic enhancer within the gene. In FN-RMS SKP2 promotes cell cycle progression and prevents differentiation directly targeting p27Kip1 and p57Kip2, respectively, unlocking a transcriptional myogenic program, partly MYOD-dependent, resulting in de novo expression of terminal muscle differentiation markers. SKP2 depletion strongly affects stemness and tumorigenic features in vitro and prevents in vivo tumor growth. The in vitro effects are mirrored by the SKP2 inhibitor SMIP004. Moreover, the investigational NEDDylation inhibitor MLN4924 hampers SKP2 functions restraining FN-RMS cell survival and tumor growth. Our results uncover a MYOD-SKP2 axis crucial for the crosstalk between transcriptional and post-translational mechanisms that contribute to FN-RMS tumorigenesis and broaden the understanding of MYOD function. Furthermore, they suggest inhibition of NEDDylation as a potential therapeutic approach in this tumor.

2023-08-30 | GSE241282 | GEO

A MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting [ChIP-seq]

2023-08-30 | GSE241279 | GEO